III期-话题@MedSci

#III期#

681篇内容 | 2781人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594966, encodeId=a45a15949664c, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Tiragolumab联合阿替利珠单抗治疗广泛期小细胞肺癌的III期研究，结果失败（SKYSCRAPER-02研究）, objectType=article, longId=302277, objectId=26843022e794, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26843022e794, replyNumber=0, likeNumber=70, createdTime=2022-04-04, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26843022e794, moduleTitle=Tiragolumab联合阿替利珠单抗治疗广泛期小细胞肺癌的III期研究，结果失败（SKYSCRAPER-02研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26843022e794)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594965, encodeId=25701594965ac, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=ARD：根据SLE患者I型干扰素基因特征和临床亚组分析Anifrolumab疗效和安全性：两项III期试验汇总数据的事后分析, objectType=article, longId=301850, objectId=439030185039, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=439030185039, replyNumber=0, likeNumber=50, createdTime=2022-03-30, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=439030185039, moduleTitle=ARD：根据SLE患者I型干扰素基因特征和临床亚组分析Anifrolumab疗效和安全性：两项III期试验汇总数据的事后分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=439030185039)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594964, encodeId=28d3159496414, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=BMC Cancer：不能切除的III期NSCLC患者cCRT后接受durvalumab维持治疗的血液学检查变化, objectType=article, longId=301652, objectId=9f863016522e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f863016522e, replyNumber=0, likeNumber=72, createdTime=2022-03-27, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f863016522e, moduleTitle=BMC Cancer：不能切除的III期NSCLC患者cCRT后接受durvalumab维持治疗的血液学检查变化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f863016522e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594971, encodeId=9a9715949e11e, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期, objectType=article, longId=301595, objectId=0e1630159509, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e1630159509, replyNumber=0, likeNumber=63, createdTime=2022-03-26, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e1630159509, moduleTitle=III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e1630159509)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594962, encodeId=1a72159496287, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Fezolinetant治疗中度至重度血管舒缩症状，III期研究未达到主要终点, objectType=article, longId=301019, objectId=aafd3010194a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aafd3010194a, replyNumber=0, likeNumber=91, createdTime=2022-03-19, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aafd3010194a, moduleTitle=Fezolinetant治疗中度至重度血管舒缩症状，III期研究未达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aafd3010194a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594963, encodeId=5c47159496301, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Chin J Cancer Res：韩宝惠教授团队III期研究表明QL1101和贝伐珠单抗治疗非鳞状非小细胞肺癌疗效相当, objectType=article, longId=300931, objectId=f500300931ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f500300931ea, replyNumber=0, likeNumber=70, createdTime=2022-03-18, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f500300931ea, moduleTitle=Chin J Cancer Res：韩宝惠教授团队III期研究表明QL1101和贝伐珠单抗治疗非鳞状非小细胞肺癌疗效相当, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f500300931ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594961, encodeId=ad6b1594961b8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=J Clin Oncol：国内多中心III期研究表明局部进展期直肠癌术前短程放疗+化疗（TNT）是可行的治疗方案, objectType=article, longId=300860, objectId=e92c300860d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e92c300860d9, replyNumber=0, likeNumber=169, createdTime=2022-03-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e92c300860d9, moduleTitle=J Clin Oncol：国内多中心III期研究表明局部进展期直肠癌术前短程放疗+化疗（TNT）是可行的治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e92c300860d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594960, encodeId=37d2159496084, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Clin Cancer Res：III期临床研究CATNON表明IDH野生型的胶质母细胞瘤中，在放疗的基础上加用替莫唑胺并不能改善患者的预后, objectType=article, longId=300739, objectId=32fb300e39e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32fb300e39e8, replyNumber=0, likeNumber=89, createdTime=2022-03-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32fb300e39e8, moduleTitle=Clin Cancer Res：III期临床研究CATNON表明IDH野生型的胶质母细胞瘤中，在放疗的基础上加用替莫唑胺并不能改善患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32fb300e39e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594959, encodeId=a19d1594959a3, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Ther Adv Med Oncol：以人群为基础研究评估可切除II/III期食管或胃食管交界处癌患者的临床预后, objectType=article, longId=300086, objectId=ce6c30008640, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce6c30008640, replyNumber=0, likeNumber=76, createdTime=2022-03-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce6c30008640, moduleTitle=Ther Adv Med Oncol：以人群为基础研究评估可切除II/III期食管或胃食管交界处癌患者的临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce6c30008640)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594958, encodeId=202d15949580b, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Cancer Commun：国内多中心III期研究EXELOX表明XELOX和EOX方案一线治疗晚期胃癌疗效相当, objectType=article, longId=300056, objectId=2c9b300056a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c9b300056a4, replyNumber=0, likeNumber=94, createdTime=2022-03-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c9b300056a4, moduleTitle=Cancer Commun：国内多中心III期研究EXELOX表明XELOX和EOX方案一线治疗晚期胃癌疗效相当, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c9b300056a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594957, encodeId=406b159495e75, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Front Oncol：III期临床研究XELAVIRI评估一线贝伐珠单抗为基础的续观治疗对比联合治疗转移性结直肠癌（mCRC）患者的疗效, objectType=article, longId=299336, objectId=5af529933624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5af529933624, replyNumber=0, likeNumber=66, createdTime=2022-02-23, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5af529933624, moduleTitle=Front Oncol：III期临床研究XELAVIRI评估一线贝伐珠单抗为基础的续观治疗对比联合治疗转移性结直肠癌（mCRC）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5af529933624)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594956, encodeId=d0e115949562e, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=亚太III期BHV3000-310研究显示，口服降钙素基因相关肽（CGRP）受体拮抗剂，可快速和持久地缓解偏头痛, objectType=article, longId=295705, objectId=74b3295e05cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74b3295e05cf, replyNumber=0, likeNumber=75, createdTime=2022-02-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74b3295e05cf, moduleTitle=亚太III期BHV3000-310研究显示，口服降钙素基因相关肽（CGRP）受体拮抗剂，可快速和持久地缓解偏头痛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74b3295e05cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594955, encodeId=b17b159495598, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效, objectType=article, longId=295703, objectId=ea9c295e0337, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea9c295e0337, replyNumber=0, likeNumber=74, createdTime=2022-02-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea9c295e0337, moduleTitle=Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea9c295e0337)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594954, encodeId=9009159495454, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=君实生物特瑞普利单抗联合化疗作为术后辅助治疗胃癌III期临床研究完成首例患者给药, objectType=article, longId=295432, objectId=53a8295432d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53a8295432d2, replyNumber=0, likeNumber=0, createdTime=2022-02-12, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53a8295432d2, moduleTitle=君实生物特瑞普利单抗联合化疗作为术后辅助治疗胃癌III期临床研究完成首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53a8295432d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594953, encodeId=66cc1594953d4, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Clin Cancer Res: Olaparib(奥拉帕利)单药维持治疗亚洲人群铂敏感复发卵巢癌的疗效：III期临床研究L-MOCA, objectType=article, longId=295346, objectId=6f04295346b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f04295346b6, replyNumber=0, likeNumber=79, createdTime=2022-02-11, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f04295346b6, moduleTitle=Clin Cancer Res: Olaparib(奥拉帕利)单药维持治疗亚洲人群铂敏感复发卵巢癌的疗效：III期临床研究L-MOCA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f04295346b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594952, encodeId=b0ce15949528b, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Transl Lung Cancer Res: PD-L1表达水平与III期NSCLC患者使用durvalumab（德瓦鲁单抗）维持治疗疗效的关系, objectType=article, longId=295314, objectId=762829531471, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=762829531471, replyNumber=0, likeNumber=75, createdTime=2022-02-10, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=762829531471, moduleTitle=Transl Lung Cancer Res: PD-L1表达水平与III期NSCLC患者使用durvalumab（德瓦鲁单抗）维持治疗疗效的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=762829531471)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594951, encodeId=1867159495179, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=J Clin Oncol：PACIFIC研究5年生存结果提示放化疗后durvalumab（德瓦鲁单抗）持续改善III期NSCLC患者的预后，5年OS超过40%, objectType=article, longId=295111, objectId=e91429511199, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e91429511199, replyNumber=0, likeNumber=0, createdTime=2022-02-05, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e91429511199, moduleTitle=J Clin Oncol：PACIFIC研究5年生存结果提示放化疗后durvalumab（德瓦鲁单抗）持续改善III期NSCLC患者的预后，5年OS超过40%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e91429511199)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594950, encodeId=6c6c1594950d7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=BMC Cancer：阴性淋巴结(NLN)数量对III期结肠癌患者预后影响, objectType=article, longId=295099, objectId=e645295099ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e645295099ce, replyNumber=0, likeNumber=86, createdTime=2022-02-05, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e645295099ce, moduleTitle=BMC Cancer：阴性淋巴结(NLN)数量对III期结肠癌患者预后影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e645295099ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594949, encodeId=365a159494922, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, objectType=article, longId=294057, objectId=20b829405e40, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20b829405e40, replyNumber=0, likeNumber=72, createdTime=2022-01-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20b829405e40, moduleTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20b829405e40)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594948, encodeId=0913159494855, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Ther Adv Med Oncol：国内多中心头对头III期研究发现转移性结直肠癌患者二线FOLFIRI方案并不优于单药伊立替康治疗，反而毒性增加, objectType=article, longId=294046, objectId=01c32940469c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01c32940469c, replyNumber=0, likeNumber=0, createdTime=2022-01-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01c32940469c, moduleTitle=Ther Adv Med Oncol：国内多中心头对头III期研究发现转移性结直肠癌患者二线FOLFIRI方案并不优于单药伊立替康治疗，反而毒性增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01c32940469c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Tiragolumab联合阿替利珠单抗治疗广泛期小细胞肺癌的III期研究，结果失败（SKYSCRAPER-02研究）

2022-04-04

智智灵药 (审核中...)

前往app查看评论内容

#III期#

ARD：根据SLE患者I型干扰素基因特征和临床亚组分析Anifrolumab疗效和安全性：两项III期试验汇总数据的事后分析

2022-03-30

智智灵药 (审核中...)

前往app查看评论内容

#III期#

BMC Cancer：不能切除的III期NSCLC患者cCRT后接受durvalumab维持治疗的血液学检查变化

2022-03-27

智智灵药 (审核中...)

前往app查看评论内容

#III期#

III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期

2022-03-26

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Fezolinetant治疗中度至重度血管舒缩症状，III期研究未达到主要终点

2022-03-19

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Chin J Cancer Res：韩宝惠教授团队III期研究表明QL1101和贝伐珠单抗治疗非鳞状非小细胞肺癌疗效相当

2022-03-18

智智灵药 (审核中...)

前往app查看评论内容

#III期#

J Clin Oncol：国内多中心III期研究表明局部进展期直肠癌术前短程放疗+化疗（TNT）是可行的治疗方案

2022-03-17

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Clin Cancer Res：III期临床研究CATNON表明IDH野生型的胶质母细胞瘤中，在放疗的基础上加用替莫唑胺并不能改善患者的预后

2022-03-16

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Ther Adv Med Oncol：以人群为基础研究评估可切除II/III期食管或胃食管交界处癌患者的临床预后

2022-03-06

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Cancer Commun：国内多中心III期研究EXELOX表明XELOX和EOX方案一线治疗晚期胃癌疗效相当

2022-03-06

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Front Oncol：III期临床研究XELAVIRI评估一线贝伐珠单抗为基础的续观治疗对比联合治疗转移性结直肠癌（mCRC）患者的疗效

2022-02-23

智智灵药 (审核中...)

前往app查看评论内容

#III期#

亚太III期BHV3000-310研究显示，口服降钙素基因相关肽（CGRP）受体拮抗剂，可快速和持久地缓解偏头痛

2022-02-17

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效

2022-02-17

智智灵药 (审核中...)

前往app查看评论内容

#III期#

君实生物特瑞普利单抗联合化疗作为术后辅助治疗胃癌III期临床研究完成首例患者给药

2022-02-12

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Clin Cancer Res: Olaparib(奥拉帕利)单药维持治疗亚洲人群铂敏感复发卵巢癌的疗效：III期临床研究L-MOCA

2022-02-11

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Transl Lung Cancer Res: PD-L1表达水平与III期NSCLC患者使用durvalumab（德瓦鲁单抗）维持治疗疗效的关系

2022-02-10

智智灵药 (审核中...)

前往app查看评论内容

#III期#

J Clin Oncol：PACIFIC研究5年生存结果提示放化疗后durvalumab（德瓦鲁单抗）持续改善III期NSCLC患者的预后，5年OS超过40%

2022-02-05

智智灵药 (审核中...)

前往app查看评论内容

#III期#

BMC Cancer：阴性淋巴结(NLN)数量对III期结肠癌患者预后影响

2022-02-05

智智灵药 (审核中...)

前往app查看评论内容

#III期#

J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效

2022-01-17

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Ther Adv Med Oncol：国内多中心头对头III期研究发现转移性结直肠癌患者二线FOLFIRI方案并不优于单药伊立替康治疗，反而毒性增加

2022-01-17

科室
- - 订阅+
  - 更多科室
工具
服务